A.Educational package for patients, developed collaboratively with all stakeholders, particularly patients, caregivers and patient organisations. | |
B.Educational package for rheumatologists and other health professionals, developed collaboratively with all stakeholders. | |
C.Educational package for healthcare administrators, policy-makers, funders and governing bodies. | |
These educational packages could include information about one or more of the following items: | |
1. TDM | |
| |
| |
| |
| |
| |
| |
| |
2. Biopharmaceuticals | |
| |
| |
| |
| |
| |
3. Immunogenicity | |
| |
| |
| |
| |
| |
|
ADAb, antidrug antibody; RMDs, rheumatic and musculoskeletal diseases; TDM, therapeutic drug monitoring.